Skip to content
On this page:OverviewPublicationsResearchersInstitutionsOpen access
PICO Portalanswers from OpenAlex

Karus Therapeutics (United Kingdom)

InstitutionResearch output, impact & collaborations

Karus Therapeutics (United Kingdom) is a institution indexed in PICO Portal from OpenAlex.

What is known about Karus Therapeutics (United Kingdom)?

PICO Portalrecord summary

Karus Therapeutics (United Kingdom) is a research organisation in Didcot, GB. OpenAlex records 86 works and 5,313 citations for it. 32 researchers list it as their most recent affiliation.

How many works does Karus Therapeutics (United Kingdom) have?

PICO Portalindexed works

Karus Therapeutics (United Kingdom) has 86 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Karus Therapeutics (United Kingdom) have?

PICO Portalcitation count

Karus Therapeutics (United Kingdom) has 5,313 citations in the OpenAlex counts PICO Portal stores.

How many researchers are at Karus Therapeutics (United Kingdom)?

PICO Portalresearcher count

Karus Therapeutics (United Kingdom) has 32 researchers in the PICO Portal index.

What is the average h-index at Karus Therapeutics (United Kingdom)?

PICO Portalavg h-index

Karus Therapeutics (United Kingdom) has an average h-index of 115 in OpenAlex.

What is the ROR of Karus Therapeutics (United Kingdom)?

PICO Portalror

The ROR for Karus Therapeutics (United Kingdom) is on the source record.

What is the OpenAlex record for Karus Therapeutics (United Kingdom)?

PICO Portalopenalex

The OpenAlex for Karus Therapeutics (United Kingdom) is on the source record.

Who are the most-cited researchers behind Karus Therapeutics (United Kingdom)?

PICO Portaltop researchers by citations
1
Srđan Verstovšek · Myeloproliferative Neoplasms: Diagnosis and Treatment
1,624 works59,248 citations

What are the most-cited papers on Karus Therapeutics (United Kingdom)?

PICO Portalmost cited works
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, R. S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, E. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Azra Raza, Kris Vaddi, William Sun, Wei Peng, V. Sandor, Hagop M. Kantarjian, For the COMFORT-I investigators
Haematologica. 2015331 CitationsOPEN ACCESS
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi, H. Kantarjian, Jean‐Jacques Kiladjian, Jason Gotlib, F. Cervantes, Ruben A. Mesa, Nicholas J. Sarlis, Wei Peng, V. Sandor, P. Gopalakrishna, Abdel Hmissi, Viktoriya Stalbovskaya, Vikas Gupta, Claire Harrison, Srđan Verstovšek, on behalf of the COMFORT Investigators
Haematologica. 2015257 CitationsOPEN ACCESS

How much of the research on Karus Therapeutics (United Kingdom) is open access?

PICO Portalopen access share
100%OPEN ACCESS
Gold
100%
Green
0%
Hybrid
0%
Bronze
0%
Closed
0%

Related on PICO Portal

470M+ articles · 14-day free trial